NCT07161258 - A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 6, 2025

Primary Completion Date

June 8, 2027

Study Completion Date

February 13, 2029

Conditions

Relapsing Multiple Sclerosis

Interventions

DRUG

Fenebrutinib

Fenebrutinib will be administered orally.

Trial Locations (6)

RECRUITING

CNE of Lviv Reg Clin Hospital Dept of Neurology D.Halytskyi Lviv NMU, Lviv

RECRUITING

Sanatorio del Sur S.A., San Miguel de Tucumán

RECRUITING

L2IP ?Instituto de Pesquisas Clínicas Ltda., Brasília

RECRUITING

Instituto de Neurologia de Curitiba - Hospital Ecoville, Curitiba

RECRUITING

Nucleo de Pesquisa Clinica do Rio Grande do Sul NPCR, Porto Alegre

RECRUITING

Centro de Pesquisas Clinicas - CPCLIN, São Paulo

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY